BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38848383)

  • 1. Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines.
    Zhang R; Li S; Schippers K; Eimers B; Niu J; Hornung BVH; van den Hout MCGN; van Ijcken WFJ; Peppelenbosch MP; Smits R
    PLoS One; 2024; 19(6):e0304607. PubMed ID: 38848383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
    Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
    Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.
    Wang W; Liu P; Lavrijsen M; Li S; Zhang R; Li S; van de Geer WS; van de Werken HJG; Peppelenbosch MP; Smits R
    Sci Rep; 2021 Apr; 11(1):7470. PubMed ID: 33811251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B virus-related hepatocellular carcinoma and overexpression of AXIN1 induces apoptosis in hepatocellular cancer cells.
    Li J; Quan H; Liu Q; Si Z; He Z; Qi H
    Oncol Res; 2013; 20(7):281-8. PubMed ID: 23879168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
    Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
    Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling.
    Zhang R; Li S; Schippers K; Li Y; Eimers B; Lavrijsen M; Wang L; Cui G; Chen X; Peppelenbosch MP; Lebbink JHG; Smits R
    Cancer Res; 2024 May; 84(9):1443-1459. PubMed ID: 38359148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.
    Qiao Y; Wang J; Karagoz E; Liang B; Song X; Shang R; Evert K; Xu M; Che L; Evert M; Calvisi DF; Tao J; Wang B; Monga SP; Chen X
    Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIM65 triggers β-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
    Yang YF; Zhang MF; Tian QH; Zhang CZ
    J Cell Sci; 2017 Sep; 130(18):3108-3115. PubMed ID: 28754688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
    J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin signaling in hepatocellular carcinoma.
    Xu C; Xu Z; Zhang Y; Evert M; Calvisi DF; Chen X
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
    Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
    Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.
    Schaeffer S; Gupta B; Calatayud AL; Calderaro J; Caruso S; Hirsch TZ; Pelletier L; Zucman-Rossi J; Rebouissou S
    J Hepatol; 2023 Sep; 79(3):704-716. PubMed ID: 37201672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
    Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma.
    Akasu M; Shimada S; Kabashima A; Akiyama Y; Shimokawa M; Akahoshi K; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Sci Rep; 2021 Aug; 11(1):16732. PubMed ID: 34429454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.